Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6624439 | 0.95 | HSD11B1 (0.58) | HSD11B1RAB9AKMT2AFKBP1AACLY | |
| SCHEMBL6616741 | 0.90 | HSD11B1 (0.66) | HSD11B1KMT2AFKBP1AACLYLRRK2 | |
| SCHEMBL6610632 | 0.85 | HSD11B1 (0.46) | HSD11B1RAB9AKMT2AMEN1 | |
| SCHEMBL6614234 | 0.84 | HSD11B1 (0.46) | HSD11B1 | |
| SCHEMBL6687477 | 0.81 | HSD11B1 (0.51) | HSD11B1RAB9AKMT2AFKBP1AACLY | |
| SCHEMBL6699043 | 0.81 | HSD11B1 (0.51) | HSD11B1RAB9AKMT2AACLYMAPT | |
| SCHEMBL3622882 | 0.80 | HSD11B1 (0.82) | HSD11B1KMT2AALDH1A1MEN1 | |
| SCHEMBL6624850 | 0.80 | HSD11B1 (0.45) | HSD11B1RAB9AKMT2AMAPTALDH1A1 | |
| SCHEMBL6626832 | 0.80 | CCKBR (0.44) | HSD11B1KMT2AMAPTALDH1A1MEN1 | |
| SCHEMBL6624322 | 0.80 | HSD11B1 (0.55) | HSD11B1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004112779-A1 | NEW USE VII | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | claimed |
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| WO-2004112779-A1 | NEW USE VII | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885RAB9A 3799/4885KMT2A 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.